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Enhanced recovery after surgery
Gynecologic/oncology
Evidence based postoperative care1. Introduction
The “Guidelines for Pre- and Intra-operative Care in Gynecologic/
Oncology Surgery: Enhanced Recovery After Surgery (ERAS®) Society
Recommendations — Part I,” [1] examined the evidence surrounding
care elements including preoperative medical optimization, bowel
preparation, carbohydrate loading, thromboembolism prophylaxis,
skin preparation, standard anesthetic protocol and intraoperative ﬂuid31 29th StNW, Calgary, Alberta
. This is an open access article undermanagement. The goal of this article is to critically review existing evi-
dence and make recommendations for elements of postoperative care.
This effort forms the basis of the ERAS® Guideline for postoperative
care in gynecologic/oncology surgery.2. Methods
2.1. Literature search
The authors convened in July 2014 to discuss topics for inclusion —
the topic list was based on the ERAS® Colonic Surgery [2] and Rectal/the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2a
GRADE system for rating quality of evidence.
Evidence
level
Deﬁnition
High quality Further research unlikely to change conﬁdence in estimate
of effect
Moderate quality Further research likely to have important impact on conﬁdence
in estimate of effect and may change the estimate
Low quality Further research very likely to have important impact on
conﬁdence in estimate of effect and likely to change the
estimate
Very low quality Any estimate of effect is very uncertain
Reference [4].
324 G. Nelson et al. / Gynecologic Oncology 140 (2016) 323–332Pelvic [3] Guidelines which were used as templates. After the topics
were agreed upon they were then allocated amongst the group accord-
ing to expertise. The literature search (1966–2014) used Embase and
PubMed to search medical subject headings including “gynecology”,
“gynecologic oncology” and all postoperative ERAS® items (see
Table 1). Reference lists of all eligible articles were crosschecked for
other relevant studies.
2.2. Study selection
Titles and abstracts were screened by individual reviewers to identi-
fy potentially relevant articles. Discrepancies in judgmentwere resolved
by the lead (GN) and senior authors (OL, SD).Meta-analyses, systematic
reviews, randomized controlled studies, non-randomized controlled
studies, reviews, and case series were considered for each individual
topic.
2.3. Quality assessment and data analyses
The quality of evidence and recommendations were evaluated ac-
cording to the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) system (see Tables 2a and 2b) [4]whereby rec-
ommendations are given as follows: Strong recommendations indicate
that the panel is conﬁdent that the desirable effects of adherence to a
recommendation outweigh the undesirable effects. Weak recommen-
dations indicate that the desirable effects of adherence to a recommen-
dation probably outweigh the undesirable effects, but the panel is lessTable 1
Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After S
Item Recommendation
Prophylaxis against
thromboembolism
Patients should wear well-ﬁtting compression stocking
compression
Extended prophylaxis (28 days) should be given to pa
abdominal or pelvic malignancies
Postoperative ﬂuid therapy Intravenous ﬂuids should be terminated within 24 h a
solutions are preferred to 0.9% normal saline
Perioperative nutritional care A regular diet within the ﬁrst 24 h after gynecologic/o
Prevention of postoperative
ileus
The use of postoperative laxatives should be considere
The use of chewing gum should be considered
Postoperative glucose control ERAS elements that reduce metabolic stress should be
resistance and the development of hyperglycemia
Perioperative maintenance of blood glucose levels (b1
perioperative outcomes; glucose levels above this rang
infusions and regular blood glucose monitoring to avo
Postoperative analgesia A multimodal approach to analgesia should be adopte
NSAIDS/acetaminophen, gabapentin and dexamethaso
Vaginal hysterectomy
Paracervical nerve block or intrathecal morphine can
consumption
Open general gynecologic surgery
Spinal anesthesia with intrathecal morphine is recom
Alternatively, thoracic epidural analgesia (TEA) with
solutions with the addition of opiates for 24-48 h ca
Truncal nerve blocks (TAP or ilioinguinal) can be rec
undergone general anesthesia without neuraxial blo
Continuous wound inﬁltration (CWI) of local anesth
Major oncologic surgery
TEA may be considered but patients frequently requ
to TEA to achieve adequate analgesia
Laparoscopic gynecologic/oncology surgery
Lack of evidence makes it difﬁcult to recommend on
another, however a multimodal approach should be
Peritoneal drainage Peritoneal drainage is not recommended routinely in g
including for patients undergoing lymphadenectomy o
Urinary drainage Urinary catheters should be used for postoperative bla
preferably b24 h postop
Early mobilization Patients should be encouraged to mobilize within 24 hconﬁdent. Recommendations are based on quality of evidence: high,
moderate, low and very low but also on the balance between desirable
and undesirable effects; and on values and preferences. As such, consis-
tent with other ERAS® Guideline Working groups [2,5], in some cases
strong recommendations may be reached from low-quality data and
vice versa. Of note, this would be considered a modiﬁed GRADE evalua-
tion since we did not consider resource utilization when making our
recommendations [6].
3. Results
The evidence base, recommendations, evidence level, and recom-
mendation grade are provided for each individual ERAS® item below.urgery (ERAS®) Society recommendations.
Evidence level Recommendation
grade
s and have intermittent pneumatic High Strong
tients after laparotomy for High Strong
fter surgery; balanced crystalloid Moderate Strong
ncology surgery is recommended High Strong
d Low Weak
Moderate Weak
employed to reduce insulin High Strong
80–200 mg/dL) results in improved
e should be treated with insulin
id the risk of hypoglycemia
High Strong
d including use of
ne (unless contraindications exist)
Multimodal: high
NSAIDS/aceta: high
Gabapentin: moderate
Dexamethasone: low
Strong
be used to reduce pain and opioid Low Weak
mended Moderate Strong
low concentration local anesthetic
n be considered
High Strong
ommended where patients have
ckade
Moderate Strong
etic can be considered Moderate Strong
ire additional IV opioids in addition Low Weak
e analgesic intervention over
employed
Low Weak
ynecologic/oncology surgery
r bowel surgery
Moderate Strong
dder drainage for a short period Low Strong
of surgery Low Strong
Table 2b
GRADE system for rating strength of recommendations.
Recommendation
strength
Deﬁnition
Strong When desirable effects of intervention clearly outweigh the
undesirable effects, or clearly do not
Weak When trade-offs are less certain — either because of low
quality evidence or because evidence suggests desirable
and undesirable effects are closely balanced
Reference [4].
325G. Nelson et al. / Gynecologic Oncology 140 (2016) 323–3324. Postoperative thromboembolism prophylaxis
4.1. Immediate postoperative prophylaxis
Pneumatic compression stockings reduce the rate of VTE (venous
thromboembolism) when compared to observation [7]. The risk reduc-
tion is equivalent when compared to heparin [8] and improved when
combinedwith heparin [9] in gynecologic oncology patients. Graduated
compression stockings decrease the rate of DVT in hospitalized patients,
especially when combined with another method [10].
4.2. Extended postoperative prophylaxis
A large prospective cohort trial showed an increased rate of VTE
within 30 days of surgery in cancer patients [11], and extended prophy-
laxis (28 days) is now considered a common practice within major gy-
necologic oncology surgery [12]. A Cochrane review of 4 randomized
controlled trials examining extended prophylaxis has shown a decrease
in VTE (14.3% vs. 6.1%; p b 0.0005) and a decrease in symptomatic VTE
(1.7% vs. 0.2%; p = 0.02) [13]. The role of extended prophylaxis in
minimally invasive surgery is likely not necessary without other high-
risk features (elevated BMI, previous VTE, coagulopathy, decreased
mobility) [14].
4.2.1. Summary and recommendations
Patients should wear well-ﬁtting compression stockings and have
intermittent pneumatic compression. Extended prophylaxis (28 days)
should be given to patients after laparotomy for abdominal or pelvic
malignancies.
4.2.2. Evidence level
High.
4.2.3. Recommendation grade
Strong.
5. Postoperative ﬂuid therapy
Oral intake of ﬂuid and food should be started the day of surgery
whenever possible. With the commencement of oral diet and oral anal-
gesia as soon as tolerated after surgery the need for postoperative intra-
venous ﬂuids beyond 12–24 h is rarely needed in an uncomplicated
recovery. Patients can drink immediately after surgery. Flavored high
energy protein drinks prescribed three times a day are safe and can
bridge the postoperative period of building back up to a normal diet to
ensure some protein and calorie intake early in the recovery process.
They are usually 200–250 ml in volume with around 150 kJ/100 ml of
carbohydrate and 3–6 g/100mLof proteinwith the addition of vitamins,
mineral and trace elements. If intravenous ﬂuids must be maintained
then a total hourly volume of no more than 1.2 mL/kg (including
drugs, approximately 90 mL/h for a 75 kg female) should be given
[15]. Balanced crystalloid solutions are preferred to 0.9% normal saline
due to the cumulative risk of hyper-chloremic acidosis. The use of starch
solutions during the perioperative period should be limited by dose and
duration to avoid the adverse effects seen in studies on intensive carepatients such as bleeding and renal dysfunction [16]. Oliguria as low
as 20cm3/h is a normal response to surgery, and the need for further in-
travenous ﬂuid boluses should be assessed within clinical context. A
small proportion of patients undergoing major surgery will develop
SIRS (Systemic Inﬂammatory Response Syndrome) causing marked va-
sodilation and hypotension without sepsis. These patients will require
vasopressor therapy such as a noradrenaline infusion during surgery
and postoperatively until resolution.
5.1. Summary and recommendations
Intravenous ﬂuids should be terminated within 24 h after surgery.
Balanced crystalloid solutions are preferred to 0.9% normal saline.
5.2. Evidence level
Moderate.
5.3. Recommendation grade
Strong.
6. Perioperative nutritional care
A number of randomized trials on the subject of early feeding (de-
ﬁned ashaving oral intake ofﬂuids or foodwithin theﬁrst 24h after sur-
gery) have been performed in gynecologic oncology [17–20]. Effects
include accelerated return of bowel activity, reduced length of stay,
with no evidence of higher complication rates related towound healing,
anastomotic leaks, or pulmonary complications. A randomized study in
patients with ovarian cancer showed a signiﬁcantly lower rate of com-
plications for patients receiving early feeding. However, complication
rates were not different between groups when the analysis was limited
to a smaller cohort of patients undergoing intestinal resections [18,19].
It is important to note that early feeding is associated with a higher rate
of nausea, but not vomiting, abdominal distension, or nasogastric tube
use. Patient satisfaction with control of vomiting in one series was
over 90% with early feeding despite a higher incidence of nausea in
the enhanced recovery group [21].
6.1. Summary and recommendation
A regular diet within the ﬁrst 24 h after gynecologic/oncology sur-
gery is recommended.
6.2. Evidence level
High.
6.3. Recommendation grade
Strong.
7. Prevention of postoperative ileus
Laxatives are commonly usedwithin enhanced recovery protocols to
hasten the return of bowel function, but no high quality data is available
in gynecologic oncology. In one prospective, but nonrandomized trial of
20 patients undergoing open radical hysterectomy, milk of magnesia
and biscolic suppositories were well tolerated and associated with a re-
duction in hospital stay comparedwith historical controls [22]. In 68 pa-
tients undergoing hepatic resection via laparotomy, patients
randomized to magnesium hydroxide experienced a median one-day
reduction in time to passage of stool [23]. Although data are limited
and effects appear modest, continued use of laxatives is reasonable
given the low cost and side effect proﬁle.
326 G. Nelson et al. / Gynecologic Oncology 140 (2016) 323–332In patients undergoinghysterectomyand colonic resection, random-
ized trials have shown improved recoverywhen a peripheral mu antag-
onist was administered [24]. Its use in patients undergoing planned
enteric resections is reasonable, but we cannot provide a recommenda-
tion for its use at the present time as cost-effectiveness and efﬁcacy data
in patients with gynecologic malignancies continues to be collected.
Perioperative use of chewing gum had a positive effect on the incidence
of postoperative ileus (36% vs. 15%) and length of stay (1 day reduction)
in a randomized trial of patients undergoing staging for gynecologicma-
lignancies [25]. A meta-analysis of randomized trials investigating
prokinetics such as erythromycin, the cholecystokinin-like drugs,
cisapride, dopamine-antagonists, propranolol, vasopressin, and intrave-
nous lidocaine [26] or neostigmine [27] failed to demonstrate beneﬁt.
7.1. Summary and recommendations
The use of postoperative laxatives and chewing gum should be
considered.
7.2. Evidence level
Laxatives: Low.
Chewing gum: Moderate.
7.3. Recommendation grade
Weak.
8. Postoperative control of glucose
Perioperative hyperglycemia, classically deﬁned as blood glucose
levels greater than 180 to 200mg/dL is associatedwith poor clinical out-
comes including increased perioperative mortality, hospital length of
stay, ICU length of stay and postoperative infection [28,29]. Most clini-
cians would agree that prevention of perioperative hyperglycemia is a
desirable intervention, the optimal blood glucose range remains
controversial due to the potential adverse events related to iatrogenic
hypoglycaemia [30]. Clinical trials in adult surgical patients illustrate
this paradigm of outcomes with intensive insulin therapy (IIT) deﬁned
as 140 to 200 mg/dL by the American College of Physicians. The Leuven
surgical trial randomly assigned patients to IIT or conventional glucose
management with a decrease in mean blood glucose levels and ICU
mortality in the IIT group [31]. However, hypoglycemia was more fre-
quent in the IIT group. These ﬁndings were supported by meta-
analytical data from 5 randomized trials, which compared IIT to less
stringent glycemic control and demonstrated signiﬁcantly lower mor-
tality [32]. In contrast, the Normoglycemic in Intensive Care Evaluation
Survival Glucose AlgorithmRegulation (NICE-SUGAR) trial demonstrat-
ed a higher rate of severe hypoglycemia and higher 90-daymortality in
those patientswho received IIT compared to conventional glucoseman-
agement [33]. Hypoglycemia is the most common adverse effect of IIT
and can lead to unwanted morbidity such as seizures, brain damage,
and cardiac arrhythmias. As a result, more liberal blood glucose targets
of 180 to 200mg/dL are typically recommended in effort to prevent sig-
niﬁcant hyperglycemia whilst avoiding iatrogenic hypoglycemia
[34–36].
The surgical stress response triggers a cascade of sympathetic ner-
vous system and endocrine responses that include activation of the
HPA axis and increased cortisol secretion, which leads to a net increase
in peripheral insulin resistance [37]. Traditional perioperative interven-
tions such as mechanical bowel preparation, pre-operative fasting, and
slow resumption of normal diet all contribute to the relative insulin re-
sistant state noted perioperatively and have been shown to correlate
with perioperative complications and increased length of hospital stay
[38]. Several elements of enhanced recovery protocols abrogate postop-
erative insulin resistance and thereby result in lower perioperativeglucose levels without resulting hypoglycemia. Examples of key ele-
ments include avoidance of oral mechanical preoperative bowel prepa-
ration and avoidance of preoperative fasting until 2 h prior to surgery,
pre-operative carbohydrate loading along with stimulation of gut func-
tion by early resumption of postoperative oral intake and optimal ﬂuid
balance [1].
8.1. Summary and recommendation
ERAS elements that reduce metabolic stress should be employed to
reduce insulin resistance and the development of hyperglycemia. Peri-
operative maintenance of blood glucose levels (b180–200 mg/dL) re-
sults in improved perioperative outcomes. Glucose levels above this
range should be treatedwith insulin infusions and regular blood glucose
monitoring to avoid the risk of hypoglycemia.
8.2. Evidence level
Use of stress reducing elements: High.
Treating hyperglycemia above 180–200 mg/dL: High.
8.3. Recommendation grade
Strong.
9. Postoperative analgesia
Pain following gynecological abdominal surgery can be severe [39].
Uncontrolled acute post-operative pain is associated with dissatisfac-
tion [40], post-operative complications, and is a strong risk factor for de-
velopment of chronic pain [41]. Morphine is commonly used to control
post-operative pain but is associated with nausea, sedation [42], fatigue
[43] and poorer quality of recovery [44] andmay prolong time tomobi-
lization. Opioid analgesics also contribute to the development of ileus.
Therefore an enhanced recovery pathway for gynecological surgery
must employ a strategy to effectively control post-operative pain and
allow attainment of other ERAS targets such as early mobilization and
return to oral diet whilst reducing the need for opiates. Many RCTs in
the last 20 years in open surgery have focused on epidural analgesia,
which can offer excellent analgesia, reduction in the surgical stress re-
sponse, and earlier return of gut function. However the role of epidural
analgesia is now a matter of debate. With the increasing uptake of lap-
aroscopic and robotic assisted surgery the magnitude and duration of
visceral and wound pain have been markedly reduced such that good
post-operative pain control is achievable by many different analgesic
techniques, often used in combination to tackle both the visceral and
wound elements. The literature base is developing rapidly and may
well impact on future recommendations.
9.1. Multimodal analgesia
The concept of achieving analgesia through the additive or synergis-
tic effects of different types of analgesics is not new [45]. Non-steroidal
anti-inﬂammatory drugs (NSAIDs) have been extensively investigated,
both as part of amulti-modal analgesic regime aswell as for gynecologic
surgery, and are effective at reducing pain and opioid consumption and
improving patient satisfaction [46,47], and a combination of NSAID and
acetaminophen is more effective than either drug alone [48]. Both
should be administered regularly unless contraindication exists.
Gabapentin has recently become popular for treatment of post-
operative pain. A recent systematic review found that pre-emptive ad-
ministration of gabapentin for abdominal hysterectomy was effective
in reducing post-operative pain, opioid consumption and side effects
[49] and has been used in one gynecologic enhanced recovery program
[21]. However, studies have not yet identiﬁed the optimal dose, or
timing of administration. Dexamethasone appears to have analgesic
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vomiting, so may be useful as part of an ERP for gynecologic surgery.
However its analgesic effects are yet to be fully investigated and it
may cause transient post-operative hyperglycemia. Chronic administra-
tion of steroids are known to impair wound healing, although this has
not been demonstrated following administration of a course b10 days
duration [52]. Intravenous lidocaine is gaining popularity as an analge-
sic adjunct in abdominal surgery. A Cochrane analysis concluded that
there was low quality evidence of an early reduction in pain, and opioid
consumption and time to bowel recovery were reduced, though the ef-
fect on these outcomes was small [26].
9.1.1. Summary and recommendations
Amultimodal analgesia strategy should be employedwith the aimof
reducing post-operative opioid requirement. Post-operatively, opioids
should be given orally to patients who can tolerate diet. For patients un-
able to tolerate diet following surgery, then anopioid IV PCA can be used
until resumption of GI function, but the oral route should be used as
soon as possible.
Acetaminophen and NSAIDs in combination should be administered
regularly to all patients unless contraindication exists.
Dexamethasone may be administered to prevent PONV and reduce
pain, but should be used with caution in diabetic patients.
Gabapentinmay reducepain and side effects andmay be considered,
although the optimal dose is not known.
9.1.2. Level of evidence
Use of multimodal analgesia: High.
Combination of acetaminophen and NSAIDs: High.
Gabapentin: Moderate.
Dexamethasone as an analgesic: Low.
9.1.3. Recommendation grade
Strong.
9.2. Analgesia for vaginal hysterectomy
Few rigorous studies have been performed investigating analgesia in
patients undergoing vaginal hysterectomy. In one study, intra-operative
paracervical nerve block appeared to reduce post-operative pain and
morphine consumption, and although the analgesic beneﬁt appears to
be limited to the ﬁrst few hours after surgery, patients mobilized more
quickly [53]. However a Cochrane review concluded that paracervical
nerve block was ineffective for cervical dilatation [54]. One study inves-
tigated high-volume local anesthetic inﬁltration of the surrounding tis-
sues and found that although the analgesic beneﬁt was limited to the
ﬁrst four hours post-operatively, patients used less opioid analgesics
and mobilized earlier [55]. In another study, spinal anesthesia with in-
trathecal morphine and clonidine also reduced early post-operative
pain and morphine consumption, though the effect was modest [56].
Both spinal morphine and paracervical nerve block have been used to
facilitate early discharge in enhanced recovery vaginal hysterectomy
pathways [57,58].
9.2.1. Summary and recommendations
Local anesthetic inﬁltration may be effective at reducing early post-
operative pain and opioid consumption, and facilitating early mobiliza-
tion. Either paracervical nerve block or intrathecal morphine may re-
duce pain and opioid consumption after vaginal hysterectomy.
However, the effect is small.
9.2.2. Evidence level
Low.
9.2.3. Recommendation grade
Weak.9.3. Analgesia for open general gynecologic surgery
The optimal analgesic regimen for open gynecologic surgery is cur-
rently a subject of debate. Thoracic epidural analgesia (TEA) has gained
widespread acceptance in providing post-operative analgesia for major
abdominal surgery [2], and has been shown to be superior to intrave-
nous PCA [59]. TEA is effective in attenuating the surgical stress re-
sponse and reducing pain and opioid consumption for up to 72 h [59,
60] following abdominal incisions, and also has an impact on complica-
tions following abdominal surgery, reducing the time to bowel recovery
by up to 36 h and may reduce cardiac and respiratory complications in
high risk patients. TEA has been shown to effectively reduce pain fol-
lowing abdominal hysterectomy [61] and gynecologic cancer surgery
[62], and reduces time to return of gut function. However the role of
TEA in enhanced recovery surgery is now less clear: whilst analgesia
and recovery seem to be better with TEA than IV PCA, epidural failure
ratesmay be as high as 30% [63], andmany of these patients will require
supplemental opiates. Even if patients are normovolemic the sympa-
thetic block that results from TEA may result in hypotension that may
require treatment with vasopressors [64]. Patients who undergo ab-
dominal hysterectomy in ERAS protocols can target a length of hospital
stay of 1–2 days, in which case TEA may hinder achievement of other
ERAS goals such as mobilization [65] and removal of urinary catheter,
and TEA has been shown to increase hospital stay and complication
rates in gynaecologic cancer surgery [66].
Where TEA is to be used local anesthetic should be of low concentra-
tion, and should be combined with an opioid such as fentanyl. Post-
operative hypotension may require treatment with vasopressors.
Some consideration must be made to the impact on early ERAS goals
and how they will be achieved, and expert post-operative input may
be required to ensure reliable analgesia. Although epidurals sited in
the lumbar spine have an evidence base for analgesic beneﬁt in gyneco-
logic surgery, thoracic epidurals are preferred: epidurals should be sited
at the level appropriate for innervation of the surgical area, and thoracic
epidurals are likely to cause less hypotension [67] andmotor block [68]
than those in the lumbar segments.
An alternative to TEA is spinal anesthesia with low-dose intrathecal
morphine (ITM). As a single injection, this has beneﬁts over TEA in
allowing early mobilization and removal of urinary catheter as well as
facilitating early discharge fromhospital [69].When compared to a gen-
eral anesthetic without neuraxial block, spinal anesthesia with ITM sig-
niﬁcantly reduces pain and morphine consumption both for
hysterectomy [39,44,70] and this analgesic beneﬁt may persist for up
to 48h post-operatively [39,44]. The added beneﬁt of reducedmorphine
consumption is the reduced risk of post-operative ileus. Additionally
ITM appears to reduce peri-operative stress hormone release [71], im-
prove post-operative recovery [44,72] and reduce post-operative
drowsiness and fatigue, though at the expense of increased pruritus
[73]. Most studies do not indicate an increase in vomiting with low-
dose ITMwhen compared with IV PCA [39,74]. Dose-ﬁnding studies ap-
pear to show a ceiling of effect at 200 mcg [74] and doses of ITMwithin
this range do not appear to increase the risk of respiratory depression
[75]. Spinal anesthesia without long-acting opioids does not improve
post-operative pain when compared to general anesthesia [76].
Experience dictates that to improve patient acceptability of spinal
anesthesia with ITM, general anesthesia may need to be offered in addi-
tion, in which case the dose of intrathecal local anesthetic should be re-
duced to avoid intra-operative hypotension and intraoperative
narcotics should be minimized to reduce side effects.
Where patients have undergone general anesthesia without
neuraxial blockade, truncal nerve blocks may serve to reduce pain and
reduce post-operative morphine requirement. Transversus abdominis
plane (TAP) blocks involve the injection of a large volume of local anes-
thetic in between the muscle layers of the trunk, and may now be per-
formed under ultrasound guidance to ensure accurate delivery of local
anesthetic. This technique has been shown to be efﬁcacious for
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meta-analysis concluded that TAP blocks reduce pain andmorphine re-
quirement up to 24 h after open gynecologic surgery [79]. In patients
undergoing Cesarean section, TAP blocks appear to be less effective
than intrathecal morphine at controlling post-operative pain, although
side effects were fewer than ITM [80] and TAP blocks do not appear to
add any analgesic beneﬁt when used in combination with ITM [81]. Bi-
lateral ilioinguinal nerve blocks also appear to reduce post-operative
morphine requirement, however may not reduce morphine-related
side effects [82].
Wound inﬁltration with local anesthetic is safe and easy to perform,
though any effect on post-operative pain and opioid consumption is
modest and short-lived [83]. Prolongation of this analgesic effect may
be achieved through insertion of sub-cutaneous wound catheters [84].
A meta-analysis concluded that continuous wound inﬁltration (CWI)
reduced pain and opioid consumption and improved recovery after
major abdominal surgery [85], and may provide analgesia equivalent
to TEA for abdominal surgery [86]. Another study found that, when
compared to TEA for open colorectal surgery, CWI reduced opioid
usage, vomiting and time to bowel recovery, and improved patient sat-
isfaction [87]. However for gynecologic surgery the data is less clear, and
although CWI has been shown to improve analgesia, reduce opioid re-
quirements and reduce time to return of gut function [88] a number of
studies have either only demonstrated beneﬁt in the ﬁrst few hours
after surgery [84], or failed to demonstrate beneﬁt at all [89–91].
There is lack of agreement concerning ideal catheter placement [92,
93], though in most studies the infusion catheter was placed below
the abdominal fascia. The impact of continuous wound inﬁltration on
wound healing has not been fully studied, though existing data has
not shown an increase in wound complication rates. More research
with this technique is required in this patient group before any conclu-
sions may be drawn.
Intraperitoneal local anesthetic (IPLA) has been utilized to reduce
post-operative pain, and one trial demonstrated reduced opioid con-
sumption and improved surgical recovery score when used alongside
TEA following colorectal surgery [94]. A systematic review of other trials
concluded that IPLA reduces post-operative pain but not opioid con-
sumption, and recovery parameters were unchanged [95]. IPLA has
also been tested for open hysterectomy and has been found to reduce
post-operative pain [96] and morphine consumption [97], however
the beneﬁtwas limited to the ﬁrst fewhours after surgery, and analgesia
from IPLA does not seem to be dose-responsive [98].
9.3.1. Summary and recommendations
For open surgery a multimodal, opiate sparing analgesic strategy
should be utilized. TEA or spinal anesthesia with intrathecal morphine
may improve recovery parameters and are recommended. However
TEAmay increase time to mobilization and removal of urinary catheter,
and may potentially impact on hospital stay.
Where patients have undergone general anesthesia without
neuraxial blockade, a truncal block, such as TAP blocks, may reduce
pain and opioid consumption for up to 24 h and should be employed.
Continuouswound inﬁltration or intraperitoneal instillation of local an-
esthetic may improve recovery for colorectal surgery and may be con-
sidered as an alternative to TAP blocks or TEA, however the evidence
of beneﬁt in gynecologic surgery is lacking.
Post-operatively, multimodal analgesia should be used. Systemic
opioids may be given either orally or by intravenous PCA. The IV PCA
should be discontinued when normal gut function resumes.
9.3.2. Evidence level
Intrathecal morphine: Moderate.
Thoracic epidural analgesia: High.
TAP blocks: Moderate.
CWI: Moderate.9.3.3. Recommendation grade
Strong.
9.4. Analgesia for major oncologic surgery
In patients undergoing cytoreductive surgery, the large surgical area
and complex patient pain history means that post-operative pain is
often severe. TEA is widely used, and was associated with superior
pain control at rest and on movement for the ﬁrst 3 post-operative
days in one observational study [99], and a randomized controlled
study [100] found improved pain control on coughing for the ﬁrst 3
post-operative days. However other investigators found no beneﬁt in
pain, bowel recovery or length of stay in patients with peri-operative
TEA, and an increase in vasopressor requirement [101]. In patients un-
dergoing heated intraperitoneal chemotherapy (HIPEC), the use of
TEA is controversial. TEA may reduce opioid consumption and reduce
time to extubation [102] although an IV PCA is often required in addi-
tion to TEA to achieve adequate analgesia [103]. HIPECmay be associat-
ed with a post-operative coagulopathy that may complicate removal of
the epidural catheter, however in one study removal of epidural cathe-
ter was delayed in only 0.5% of cases [104]. Some centers use intrave-
nous PCA in preference to TEA, citing adequate analgesia with fewer
hemodynamic effects [105]. TAP blocks were examined in one retro-
spective study and appeared to reduced opioid consumption on post-
operative day 1 only [106].
9.4.1. Summary and recommendations
TEA is effective in reducing post-operative pain after gynecologic
laparotomy. However TEA may not improve other post-operative out-
comes and patients may require additional IV opioids in addition to
TEA to achieve adequate analgesia. TEA may compound hypotension
that requires vasopressor support. Intravenous PCA appears to be a suit-
able alternative.
9.4.2. Evidence level
Low.
9.4.3. Recommendation grade
Weak.
9.5. Analgesia for laparoscopic gynecologic/oncology surgery
A meta-analysis examining TAP blocks for laparoscopic surgery
across a range of abdominal procedures [107] found only pain at rest,
and not dynamic pain, was reduced. For laparoscopic hysterectomy,
one trial showed that TAP blocks improved post-operative quality of re-
covery (QoR40) score [108] however 3 further trials did not show ben-
eﬁt [109–111]. Intra-peritoneally administered local anesthetic has
been used successfully for minor gynecologic laparoscopic procedures
but this technique does not seem to be effective for major gynecologic
laparoscopic surgery, either by single instillation or continuous infusion
[112–116]. Additionally, a Cochrane analysis of intraperitoneal local an-
esthetic for laparoscopic cholecystectomy found low quality evidence of
beneﬁt, though the effect was likely to be clinically insigniﬁcant [117].
ITM showed a small beneﬁt in robotic surgery [118]. TEA has been in-
vestigated for laparoscopic colorectal surgery and appeared to prolong
hospital stay without improving patient outcomes [69].
9.5.1. Summary and recommendations
For laparoscopic gynecologic/oncology surgery, neither TAP blocks
nor intraperitoneal instillation of local anesthetic are recommended
on the current level of evidence. For laparoscopic abdominal surgery,
TEA may prolong hospital stay without improving outcomes. Multi-
modal analgesia should be employed, and post-operative opioids may
be given either orally or by IV PCA depending on magnitude of surgery
and predicted post-operative gut function.
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Low.
9.5.3. Recommendation grade
Weak.
10. Peritoneal drainage
Peritoneal drainage has traditionally been used to prevent accumu-
lation of ﬂuid in the bed of dissection, to evacuate blood, serous collec-
tions, or infection, and in colorectal surgery it has been thought to
prevent anastomotic leakage. However, peritoneal drainage has not
been shown to prevent anastomotic leaks or improve overall outcome,
and is not recommended routinely after either colonic or rectal surgery
[119–121]. There is little research regardingdrains after colonic or rectal
anastomosis in gynecologic oncology surgery [122]. It is difﬁcult to ex-
trapolate the results from the colorectal literature directly to all gyneco-
logical surgery. For patients withmetastatic ovarian cancer, the scope of
surgery is larger, encompassing other organ resections,most of the peri-
toneal surfaces, and the risk factor proﬁle for postoperative morbidity is
elevatedwith poor nutritional status, ascites, peritoneal carcinomatosis,
extended operative times, and cytotoxic therapy. Regardless, the rate of
anastomotic leakage in ovarian cancer surgery in the literature ranges
from1 to 7%, in the range found in colorectal surgery [122–124]. In sum-
mary, we did not ﬁnd evidence that drainage gives better outcomes
after gynecological surgery. Furthermore, a Cochrane systematic review
including 4 studies with 571 participants [125] concluded that drains
did not prevent lymphocysts, but were rather associated with a higher
risk of cyst formation after pelvic lymphadenectomy. Fewer studies
have investigated para-aortic lymphadenectomy, but no evidence exists
to recommend drainage [126]. Urological surgical techniques are
frequently employed duringmajor gynecologic oncology cases. Histori-
cally drains have been placed at the site of bladder resection/reconstruc-
tion, ureteral reimplantation, and urinary diversion (ileal conduit,
continent reservoir)with the aimof identifying early urine leaks. Never-
theless, there are no speciﬁc studies that have evaluated the use of
drains in such surgeries in our patient population. Looking to the uro-
logical literature, it should be noted that the ERAS Radical Cystectomy
guideline found no evidence to support or refute the use of drains in
this setting and as such further research is required in this area [5].
10.1.1. Summary and recommendation
Peritoneal drainage is not recommended routinely in gynecologic/
oncology surgery including for patients undergoing lymphadenectomy
or bowel surgery.
10.1.2. Evidence level
Moderate.
10.1.3. Recommendation grade
Strong.
11. Urinary drainage
The primary indications for postoperative bladder drainage are to
monitor urine output and prevent urinary retention. However, there is
considerable variation in the method and duration of bladder drainage
following surgery for gynecological cancers. In addition, there is a high
incidence of bladder related morbidity to the lower genital tract follow-
ing such surgery, which may include effects on urinary voiding and
bladder capacity [127].
A review of policies for removal of short-term urinary catheters
identiﬁed only a small number of studies including patients undergoinggynecologic surgery [128]. When comparing the timing of removal of
the catheter, time to ﬁrst voiding was longer, but larger volumes of
urine were passed following midnight removal compared to early
morning. In one study, midnight removal of catheters was also associat-
ed with signiﬁcantly shorter length of stay [129]. A recent single center
study following uncomplicated total abdominal hysterectomy com-
pared removal of urethral catheters immediately after surgery, 6 h, or
24 h postoperatively. The intermediate group had fewer re-
catheterizations compared to the immediate removal group, and
lower rates of urinary tract infection than the prolonged users [130].
These ﬁndings are supported by a recent review [131]. In the same re-
view, a greater number of patients required re-catheterization following
a urethral compared to a suprapubic catheter. Two small studies focus-
ing on patients undergoing radical hysterectomy for cervical cancer
showed the suprapubic route to be associated with fewer bladder infec-
tions [132,133]. In one of these studies intermittent self- catheterization
was associated with a higher infection rate but patients found the tech-
nique to be catheterization [133].
11.1.1. Summary and recommendation
Urinary catheters should be used for postoperative bladder drainage
for a short period preferably b24 h postoperatively.
11.1.2. Evidence level
Low.
11.1.3. Recommendation grade
Strong.
12. Early mobilization
There are multiple hypothesized beneﬁts to early mobilization, in-
cluding a reduction in pulmonary complications, decreased insulin re-
sistance, less muscle atrophy, and reduced length of hospital stay [134,
135]. Early mobilization has been shown to be an integral part of sys-
tematic efforts to reduce venous thromboembolic complications in the
surgical patient [136]. Foley catheters, poor pain control, and IV poles,
have been identiﬁed by gynecologic surgical patients as barriers to am-
bulation [137]. Therefore, compliance with other aspects of enhanced
recovery protocols may improve early mobilization by limiting these
barriers [138]. A care plan listing daily mobilization goals and patient
engagement with an activity diary may be helpful [135,139].
12.1.1. Summary and recommendation
Patients should be encouraged to mobilize within 24 h of surgery.
12.1.2. Evidence level
Low.
12.1.3. Recommendation grade
Strong.
13. Discussion
This guideline outlines the recommendations of the ERAS®Group for
the postoperative management of patients undergoing gynecologic/
oncology surgery, and is based on the best available evidence. As was
the case in Part I [1], in some instances good quality data was not avail-
able. This was particularly true for the evidence surrounding urinary
drainage, early mobilization and postoperative analgesia in which the
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surgery is currently a subject of debate. In some instances recommenda-
tions were made based on ﬁndings from other surgical disciplines in
which major abdominal surgery is routinely utilized.
We are hopeful that these gynecologic/oncology ERAS® guidelines
will help integrate existing knowledge into practice, align perioperative
care, and encourage future investigations to address existing knowledge
gaps. Measuring compliance has proven to be a key factor required for
success and sustainability of ERAS® protocols [140]. A process is cur-
rently underway whereby the gynecologic/oncology guidelines are
being translated into their corresponding audit system (ERAS Interac-
tive Audit System, EIAS) which will help to ensure compliance [141]
and allow surgeons/clinicians to improve the care delivered to our pa-
tient population.
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